By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Sequenom were up 14 percent in mid-afternoon trade on the Nasdaq after the firm announced earlier today the launch of its SensiGene Fetal (XY) test through its CLIA lab, the Sequenom Center for Molecular Medicine.

The new SensiGene test is a non-invasive assay that detects circulating cell-free fetal DNA in maternal blood. It interrogates male specific targets on the Y chromosome and runs on Sequenom's MassArray system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.